Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Investor2 who wrote (9575)	4/30/2020 9:37:03 AM
From: Kirk ©	Respond to of 26505

I saw the text.... "maybe." Any idea when they will have proper scientific studies completed with any of these promising regimes? The press, hell bent on presenting one political side of the other, seems to leave off most reporting that many of these studies only look at one area of use. For example, giving a Hydroxycholoquine to patients late in the disease cycle isn't nearly as helpful as giving it to them early. We've seen Remdesivir work so well at helping patients before they are on ventilators that they stopped the study early to give the drug to those given placebos. A study out a week or so before said Remdesivir was not helpful to give it to patients on ventilators as most of those die with our without it. We know from this study I posted AGES ago that both work early in cell models: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro nature.com Letter to the Editor Open Access Published: 04 February 2020 Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. Since these compounds have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease. To me, it seems just a matter of designing proper tests (Phase 1, 2 & 3 studies) to determine dose and timing for both as treatments. It appears this is ongoing with some getting all bent out of shape as results trickle in.